An undisclosed settlement ends an Actos bladder cancer trial that has been ongoing since late August and follows a larger settlement agreement affecting thousands of cases.
A $2.4 billion Actos settlement can go forward now that enough plaintiffs have agreed to participate, the manufacturer has announced.
A new Actos trial is under way in Las Vegas, over claims that warnings were withheld about the risk of bladder cancer.
A California appeals court has ruled that a judge wrongly overturned a $6.5 million verdict against Takeda Pharmaceuticals over claims that Actos caused bladder cancer.
An Actos settlement agreement has been reached that will result in Takeda Pharmaceuticals paying about $2.4 billion to resolve bladder cancer claims.
A string of settlement negotiations have been scheduled over the next year in hopes of resolving thousands of Actos bladder cancer claims without the need of lengthy and expensive trials.
A federal judge is calling for a round up of the status of Actos litigation following a string of court losses by the manufacturer.
From a medical device that spreads cancer to auto defects that may have caused hundreds of accidents and deaths, these are the top consumers risks uncovered in 2014.
A $9 billion Actos bladder cancer punitive damage award has been reduced to the highest amount allowed under law, according to the trial judge.
A Philadelphia jury has ordered Takeda Pharmaceuticals to pay $2 million for not warning that Actos can cause bladder cancer.
